Middle East Pharmaceutical Industries Co.
Last Updated:
- 135.40 SAR
- -1.20
- -0.88%
شركة الشرق الأوسط للصناعات الدوائية
أفالون فارما
Symbol :
4016
ISIN :
SA160G51UO10
52-Week Range :
108.00
-
140.60
Turnover Ratio :
0.53
Market :
Saudi Exchange
Sector :
Pharma, Biotech & Life Science
Industry :
Health Care Supplies
Sub-Industry :
Basic Information
-
Activity :Middle East Pharmaceutical Industries Co. (known as: AVALON PHARMA) is a public company, listed on Saudi Exchange “Tadawul” (TDWL) since Februry 2024. AVALON PHARMA operats within the pharmaceuticals Research...
-
Industry Group :Health care supplies & services
-
Sub-Industry :
-
ISIN :SA160G51UO10
-
Contact Person :
-
Established On:29-Jun-1998
-
Stock Listing On :27-Feb-2024
-
No of Employees :632 Employees as of 2024
-
Outstanding Shares :20,000,000
-
Free Float Shares :
-
Par Value :
-
Paid Capital :
-
Market Cap :
-
Authorized Capital :
Indices Membership
| Action | Date | Index | Provider |
|---|---|---|---|
| Join | 2024 | Pharma, Biotech & Life Science | Saudi Exchange |
| Join | 2024 | Tadawul All Share Index (TASI) | Saudi Exchange |
| Middle East Pharmaceutical Industries Co. |
| Second Industrial City, PO Box 3800, Riyadh 14331, Kingdom of Saudi Arabia |
| T : +966 11 8365000 |
| F : +966 11 2360856 |
| www.avalonpharmaceutical.com |
| investor.relations@avalon.com.sa |
Management
| Title | Name | As Of |
|---|---|---|
| Chairman: | Ahmed Altabbaa | 2022 |
| CEO: | Mohammed Al Ghannam | 2022 |
| Deputy Chairman: | Hisham Attar | 2023 |
| Board Member: | Faisal Aljaman | 2022 |
| Omar Al Jaroudi | 2023 |
Reports
| Date | Title | File |
|---|---|---|
| 2025 | AVALON PHARMA Quarterly Financials Report Q2 2025 | |
| 2025 | Avalon Pharma Signs Strategic Agreement with Adalvo for Obesity Treatments | |
| 2025 | AVALON PHARMA Quarterly Financials Report Q1 2025 | |
| 2025 | AVALON PHARMA Annual Financials Report 2024 | |
| 2025 | Avalon Pharma Earnings Release Financial Year 24 | |
| 2024 | AVALON PHARMA Quarterly Financials Report Q3 2024 | |
| 2024 | AVALON PHARMA Quarterly Financials Report Q2 2024 | |
| 2024 | AVALON PHARMA Quarterly Financials Report Q1 2024 | |
| 2024 | Avalon delivers strong start to 2024 with a remarkable 37% increase in revenue, high profitability and substantial rise in net profit | |
| 2024 | AVALON PHARMA Annual Financials Report 2023 | |
| 2024 | Middle East Pharmaceutical Industries Company(“Avalon Pharma”) Announces the Final Offer Price |
